64P - Effects of rottlerin and genistein through EF2K on proliferation, invasion and cell cycle/death in neuroblastoma cells

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Basic Science
Presenter Mumin Erdogan
Citation Annals of Oncology (2017) 28 (suppl_5): v1-v21. 10.1093/annonc/mdx361
Authors M.A. Erdogan, O. Alkan Yılmaz
  • Physiology, Ege University Faculty of Medicine Department of Physiology, 35000 - Izmir/TR

Abstract

Background

Neuroblastoma (NB) is the most common extracranial solid cancer in childhood and the most common cancer in infancy in the world. Rottlerin, a naturally occurring polyphenolic compound derived from Mallotus philipinensis, appears to have great potential in cancer therapy because of its effects on proliferation and apoptosis. Genistein is a phytoestrogen and it has been found to inhibit uncontrolled cell growth in several cancers. Recently, we learned that eukaryotic elongation factor-2 kinase (EF2K) is dramatically upregulated in many cancer cells and promotes cell survival and proliferation. Rottlerin and genistein have also showed inhibitory effects on this kinase in other solid tumours like pancreatic cancer. With this is mind, we investigated the effects of rottlerin and genistein in neuroblastoma cells.

Methods

In this study, two human neuroblastoma cancer cell lines (SH-SY5Y and Kelly) were treated with rottlerin and genistein in vitro. Cell proliferation, colony formation and invasion were assessed, and wound-healing tests, western blots (wb), cell cycle and apoptosis analysis by flow cytometry were performed.

Results

Our results showed that rottlerin and genistein treatments caused a significant reduction in cell proliferation, colony formation, and invasion/wound-healing capacity in neuroblastoma cells at concentrations of 5 µM and 30 µM, respectively (p 

Conclusions

In conclusion, these results indicate that rottlerin and genistein have important effects on neroblastoma cell behaviour and these effects may be caused by downregulation of EF2K.

Clinical trial identification

Legal entity responsible for the study

Mumin Alper Erdogan

Funding

None

Disclosure

All authors have declared no conflicts of interest.